May 16th, 2022 - Let’s Connect at ASGCT. Stop by our Booth #260 and learn about our patented CpG-depletion technology for safe, effective, and durable transgene expression following AAV gene transfer.

Let NxGEN design your AAV vector sequence and reduce the number of inflammatory CpG di-nucleotide motifs to get your platforms up and running faster with the greatest success rate.

March 15th, 2022 - Let’s Connect at the American Society of Gene and Cellular Therapy Meeting in May 2022, Washington, D.C. at Booth 260!

Visit our exhibit booth to hear more about our patented CpG-depletion AAV vector technology, our custom CpG-depleted AAV vector construct generation and consulting services, and to pick up our promotional custom stress ball of an AAV virus.

February 28th, 2022 - A review article in Molecular Therapy available online March 10, 2022, explores the non-immunological and immunological processes that may limit or improve durability and the strategies that can be employed to increase the duration of the therapeutic effect. The authors suggest CpG- depletion of AAV vectors as one strategy to enhance long-term transgene expression.

Click here to read the article

November 1st, 2021 - AAV Vector Construct Design and Consulting Services: Did you know that NxGEN Vector Solutions offers AAV vector construct generation and consulting services?

We apply our industry experience in AAV vector design and immunology to address the unique challenges of the Gene Therapy field. Our team of experienced Gene Therapy professionals bring deep expertise in CpG-depleted AAV vector design to overcome immune responses and to assist our clients in achieving their R&D objectives. 

Please fill out the form on our Consulting/Contact Us page and select the ‘Consulting’ option or feel free to send an email to We look forward to working with you!

September 8th, 2021 - Dr. Susan Faust is an invited guest speaker presenting at the Gene Therapy Summit, Vector Engineering & Design, taking place in Boston, MA on Apr 12, 2022

1) Short Course: Capsid or Genome: What’s Causing the Transgene-Limiting Immune Response Following AAV Gene Transfer?

2) Podium Presentation: Adeno-Associated Virus (AAV) Gene Transfer of a Localized Immunosuppressant in Cardiac Transplants for the Prevention of Chronic Rejection

July 14th, 2021 - NxGEN Vector Solutions’ CEO, Dr. Susan Faust, is an invited guest speaker at the #VLGeneCellGene and Cell Therapies: CMC, CGT & Vector Manufacturing Summit

November 18-19, 2021| 9:00 CEST |Munich, Germany & Online

Dr. Faust will be speaking on:

  • The desirability of CpG depletion of AAV vectors for the purpose of reducing the immune response to the vector and establishing long-term transgene expression
  • The mechanism by which immunostimulatory CpG motifs limit transgene expression (presenting data from both preclinical and clinical studies) as well as strategies for the future design of AAV vectors

May 24th, 2021 - NxGEN Vector Solutions Announces Issuance of a New U.S. Patent Covering CpG-depleted AAV Vector Technology

May 25th, 2021—NxGEN Vector Solutions announces today that the U.S. Patent and Trademark Office has issued a new Patent, No. 11,015,210, further strengthening the Company’s intellectual property position and coverage for the Company’s CpG-depletion AAV Vector Technology.

The ‘210 patent, entitled, “Constructs and Methods for Delivering Molecules via Viral Vectors with Blunted Innate Immune Responses,” covers a modified recombinant adeno-associated viral vector to reduce the number of CpG di-nucleotides such that an immune response to the vector is reduced.

There are four independent claims and they are drawn to various AAV vector compositions in which the regulatory sequence and the exogenous sequence of the AAV vector is CpG-reduced or CpG-free and the AAV ITRs are wild type or CpG-reduced. The regulatory sequence can be a promoter, an enhancer, an intron, a microRNA, or a polyA signal sequence.

The issued patent demonstrates NxGEN Vector Solutions’ commitment to developing innovative therapies that improve AAV gene therapy outcome by establishing persistent transgene expression, evading immunity, and minimizing infiltration of effector cells. We are pleased with the issuance of the patent and excited about the potential of this technology–which is already being used in clinical trials and has quickly become an industry standard–to improve the safety and efficacy of gene therapies and to ensure that patients who receive gene therapy maintain their therapeutic gene expression.

Click here to view the Patent

April 20th, 2021 - 2021—Read the original CpG-depletion AAV vector technology scientific article, Faust et al., JCI, 2013. We were the first to develop and demonstrate that CpG-depleted AAV vectors could establish persistent transgene expression, evade immunity, and minimize infiltration of effector cells. We concluded and accurately predicted that CpG-depleted AAV vectors could improve outcome of clinical trials of gene therapy.

Click here for the full article